Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 study of BBT-401 in China

Next Previous
Trial Profile

A phase 1 study of BBT-401 in China

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BBT-401 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 19 Oct 2021 According to a Bridge Biotherapeutics media release, the first subject has been dosed in Chengdu, China. The Fifth People's Hospital of Chengdu has been selected as the clinical trial site for the study.
  • 19 Oct 2021 Status changed from planning to recruiting, according to a Bridge Biotherapeutics media release.
  • 26 Dec 2019 According to a Bridge Biotherapeutics media release, company plans to initiate this study in Chinese subjects in May 2020, and expected to complete by end of 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top